Adjuvant chemotherapy – the dark side of clinical trials Have we learnt more?-Reference-Cited by-同舟云学术

Adjuvant chemotherapy – the dark side of clinical trials Have we learnt more?

Published:2009-10 Issue: Volume:18 Page:S18-S24
ISSN:0960-9776
Container-title:The Breast
language:en
Short-container-title:The Breast

Author:

Oakman Catherine,Pestrin Marta,Cantisani Egidia,Licitra Sara,DeStefanis Matilde,Biganzoli Laura,Di Leo Angelo

Publisher

Elsevier BV

Subject

General Medicine,Surgery

Reference47 articles.

1. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer;Paik;N Engl J Med,2004

2. Molecular portraits of human breast tumours;Perou;Nature,2000

3. Estrogen receptor analysis for breast cancer: Current issues and keys to increasing testing accuracy;Diaz;Adv Anat Pathol,2005

4. Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer;Fisher;J Natl Cancer Inst,2001

5. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal, node-positive, ER-positive breast cancer (S8814, INT0100);Albain;Breast Cancer Res Treat,2007

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Alterations in the p53 isoform ratio govern breast cancer cell fate in response to DNA damage;Cell Death & Disease;2022-10-28

2. Novel sesquiterpene lactone analogues as potent anti-breast cancer agents;Molecular Oncology;2016-03-25

3. DNA Repair Based Therapy in Oncology and Neurodegeneration;Advances in DNA Repair;2015-11-18

4. Taxol, Camptothecin and Beyond for Cancer Therapy;Advances in Botanical Research;2012

5. Classical lobular breast carcinoma consistently lacks topoisomerase-IIα gene amplification: implications for the tailored use of anthracycline-based chemotherapies;Histopathology;2011-12-14